Agenda

Articles

• FEDER
  16 March 2022, by Jonathan NOWAK

  Vect Horus a reçu l’accord de la Région Sud Provence-Alpes-Côte d’Azur, responsable de la mise en œuvre du dispositif REACT-EU dans le cadre du Programme Opérationnel FEDER-FSE, pour une subvention de 1 146 069 €.
  Vect-Horus développe sa plateforme technologique VECTrans® unique en Europe dont l’objectif est de développer des molécules « vecteurs » qui permettent le ciblage et la délivrance d’agents d’imagerie ou thérapeutiques dans des organes spécifiques. Cette stratégie est centrale, en (…)

• Vect-Horus will participate to the HealthTech Innovation Days on November 13-14, 2022
  11 October 2022, by Elodie DORMES

  Elodie DORMES, Business Development Manager, will attend the HealthTech Innovation Days in Paris on November 13-14, 2022.
  2 days dedicated to networking and interaction with Biotech and Pharmaceutical companies.

• Vect-Horus will attend to BioJapan Digital Conference
  30 September 2021, by Elodie DORMES

  Elodie DORMES, BD Manager, will attend to the BioJapan Digital Conference, starting the 12th of October 2021 and ending the 15th of October. 4 days dedicated to digital networking and interaction with Biotech and Pharmaceutical companies needing to enhance the delivery of Key candidate compounds to the brain or other organs and tumours.

• Vect-Horus will be attending the EANM’19 Congress in Barcelona
  3 September 2019, by Elodie DORMES

  Cedric MALICET PhD, Oncology Project Manager and Elodie DORMES, Business Development Manager will attend EANM from 12-16 October, 2019 in Barcelona to discuss Peptide Receptor Radionuclide Therapy strategy and partnered Vect-Horus’ products.

• Vect-Horus will be attending the BiotechShowcase 23
  12 January 2023, by Elodie DORMES

  From January 18 to 19, Emmanuelle Bettendorf will participate in the virtual #BiotechShowcase at #JPM23 and will be available to e-meet with you on partnership opportunities.

• Meet Vect-Horus at OTS, Montreal, October 6-9, 2024
  2 October 2024, by Emmanuelle BETTENDORF

  Guillaume Jacquot and Emmanuelle Bettendorf will be representing Vect-Horus at the The Oligonucleotide Therapeutics Society (OTS) Annual Meeting, taking place in Montreal, Canada from October 6-9.
  This is the leading international meeting of renowned oligonucleotide scientists, bringing academia, research and business together, and we are excited to swap notes with other leading players in the field.
  👉 Click here for more on the meeting www.2024oligomeeting.com

• Vect-Horus will be attending the EANM’18 Congress in Düsseldorf
  28 January 2019, by Jonathan NOWAK

  VECT-HORUS will present a poster on its proprietary technology platform, VECTrans®, for the targeting and delivery of imaging or therapeutic agents to tumors.
  Please come and meet Cedric MALICET PhD, Oncology Project Manager.

• Vect-Horus at Pierre Fabre DayOne Open Innovation Day
  28 January 2019, by Jonathan NOWAK

  Vect-Horus selected for an elevator pitch during DAYONE 2017: an open innovation day dedicated to pharmaceutical innovation. The one day conference aim is to identify, bring out, and develop innovative projects by biopharmaceutical companies, start-ups, and research laboratories (public or private) specialized in oncology, dermatology or consumer healthcare.
  https://www.pierre-fabre.com/en/news/applications-dayone-2017-are-open-unique-open-innovation-day-dedicated-pharmaceutical

• Vect-Horus will be attending the J.P. Morgan 36th Annual Healthcare Conference
  28 January 2019, by Jonathan NOWAK

  January 8-11, 2018 – San Francisco, CA, USA
  If you would like to arrange a one-on-one meeting with Vect-Horus’ team during the conference, please contact Jamal TEMSAMANI, Director of Drug Development & Corporate at jamal.temsamani@vect-horus.com

• CNS Barrier Congress
  28 January 2019, by Jonathan NOWAK

  22-23 March 2017 // Holiday Inn London Kensington Hotel